South Korea’s Ministry of Food and Drug Safety approved Curocell’s CAR T therapy Rimqarto (anbal-cel) as the first homegrown CAR T product for advanced diffuse large B-cell lymphoma. The approval, dated April 29, moves Rimqarto into clinical and commercial rollout in a market that has been expanding demand for locally produced cell therapies. The therapy approval signals progress for domestic manufacturing capability and regulatory pathways for advanced cell products. It also provides a new treatment option for patients who have exhausted standard therapies. For the category, homegrown approvals can reduce logistical complexity versus imported products and support broader access—particularly in regions seeking to strengthen cell-therapy supply chains. The decision will likely impact competitive dynamics among CAR T developers in the region, as additional manufacturers pursue local clinical and commercial pathways.